Desmond G. Johnston
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Desmond G. Johnston has a total of 192 co-authors. Here are the top co-authors by number of shared publications:
- Nick Oliver
Department of Metabolism, Digestion and Reproduction, Faculty of Medicine Imperial College London London UK
16 shared publications - Ian F. Godsland
Department of Metabolism, Digestion and Reproduction Imperial College London London UK
10 shared publications Ian F. Godsland
Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College, London, SW7 2AZ, UK
8 shared publications- Shivani Misra
Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
8 shared publications Akaal Kaur
Faculty of Medicine, Imperial College London, London, UK
7 shared publicationsArun Nanditha
India Diabetes Research Foundation, Chennai, India
7 shared publications
Latest Publications
- Open Access
- 10 September 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (11) , 3825-3831
Association between the English National Health Service Diabetes Prevention Programme and incident multiple long-term conditions
Existing evaluations of the National Health Service Diabetes Prevention Programme (NHS DPP) in England have demonstrated associated reductions in body weight, hemoglobin A1c and incident type 2 diabetes (T2D). In this study, we examined associations between completion of the NHS DPP and incidence of T2D and 30 other long-term conditions (LTCs), including LTCs considered linked to the programʼs interventional goals of body weight reduction, increased physical activity and improved diet quality (LTC-L) and LTCs considered to be possibly linked to those goals (LTC-PL). We found that completers of the NHS DPP had lower incidences of T2D, LTC-L and LTC-PL compared to non-attenders. Although these associations attenuated over time, they remained significant for all outcomes at 24 months with an odds ratio of 0.53 (95% confidence interval: 0.48–0.59) for T2D and rate ratios of 0.79 (0.74–0.84) and 0.80 (0.74–0.88) for LTC-L and LTC-PL, respectively. However, we were not able to directly conclude whether lower incidence rates were a direct result of completing the NHS DPP or due to residual bias stemming from unmeasured confounding and imprecision in the estimation of diagnosis.
- 10 September 2025
- Published by Springer Nature in Nature Medicine
- Vol. 31 (11) , 3825-3831
Open AccessAssociation between the English National Health Service Diabetes Prevention Programme and incident multiple long-term conditions
Existing evaluations of the National Health Service Diabetes Prevention Programme (NHS DPP) in England have demonstrated associated reductions in body weight, hemoglobin A1c and incident type 2 diabetes (T2D). In this study, we examined associations between completion of the NHS DPP and incidence of T2D and 30 other long-term conditions (LTCs), including LTCs considered linked to the programʼs interventional goals of body weight reduction, increased physical activity and improved diet quality (LTC-L) and LTCs considered to be possibly linked to those goals (LTC-PL). We found that completers of the NHS DPP had lower incidences of T2D, LTC-L and LTC-PL compared to non-attenders. Although these associations attenuated over time, they remained significant for all outcomes at 24 months with an odds ratio of 0.53 (95% confidence interval: 0.48–0.59) for T2D and rate ratios of 0.79 (0.74–0.84) and 0.80 (0.74–0.88) for LTC-L and LTC-PL, respectively. However, we were not able to directly conclude whether lower incidence rates were a direct result of completing the NHS DPP or due to residual bias stemming from unmeasured confounding and imprecision in the estimation of diagnosis.
- Top Cited PapersOpen Access
- 1 August 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (10) , 2830-2837
The burden of diabetes-associated multiple long-term conditions on years of life spent and lost
Diabetes mellitus is a central driver of multiple long-term conditions (MLTCs), but population-based studies have not clearly characterized the burden across the life course. We estimated the age of onset, years of life spent and loss associated with diabetes-related MLTCs among 46 million English adults. We found that morbidity patterns extend beyond classic diabetes complications and accelerate the onset of severe MLTCs by 20 years earlier in life in women and 15 years earlier in men. By the age of 50 years, one-third of those with diabetes have at least three conditions, spend >20 years with them and die 11 years earlier than the general population. Each additional condition at the age of 50 years is associated with four fewer years of life. Hypertension, depression, cancer and coronary heart disease contribute heavily to MLTCs in older age and create the greatest community-level burden on years spent (813 to 3,908 years per 1,000 individuals) and lost (900 to 1,417 years per 1,000 individuals). However, in younger adulthood, depression, severe mental illness, learning disabilities, alcohol dependence and asthma have larger roles, and when they occur, all except alcohol dependence were associated with long periods of life spent (11–14 years) and all except asthma associated with many years of life lost (11–15 years). These findings provide a baseline for population monitoring and underscore the need to prioritize effective prevention and management approaches.
- 1 August 2024
- Published by Springer Nature in Nature Medicine
- Vol. 30 (10) , 2830-2837
Top Cited PapersOpen AccessThe burden of diabetes-associated multiple long-term conditions on years of life spent and lost
Diabetes mellitus is a central driver of multiple long-term conditions (MLTCs), but population-based studies have not clearly characterized the burden across the life course. We estimated the age of onset, years of life spent and loss associated with diabetes-related MLTCs among 46 million English adults. We found that morbidity patterns extend beyond classic diabetes complications and accelerate the onset of severe MLTCs by 20 years earlier in life in women and 15 years earlier in men. By the age of 50 years, one-third of those with diabetes have at least three conditions, spend >20 years with them and die 11 years earlier than the general population. Each additional condition at the age of 50 years is associated with four fewer years of life. Hypertension, depression, cancer and coronary heart disease contribute heavily to MLTCs in older age and create the greatest community-level burden on years spent (813 to 3,908 years per 1,000 individuals) and lost (900 to 1,417 years per 1,000 individuals). However, in younger adulthood, depression, severe mental illness, learning disabilities, alcohol dependence and asthma have larger roles, and when they occur, all except alcohol dependence were associated with long periods of life spent (11–14 years) and all except asthma associated with many years of life lost (11–15 years). These findings provide a baseline for population monitoring and underscore the need to prioritize effective prevention and management approaches.
- Open Access
- 10 November 2022
- Published by Springer Nature in Diabetologia
- Vol. 66 (2) , 310-320
The relationship between islet autoantibody status and the genetic risk of type 1 diabetes in adult-onset type 1 diabetes
Aims/hypothesis: The reason for the observed lower rate of islet autoantibody positivity in clinician-diagnosed adult-onset vs childhood-onset type 1 diabetes is not known. We aimed to explore this by assessing the genetic risk of type 1 diabetes in autoantibody-negative and -positive children and adults. Methods: We analysed GAD autoantibodies, insulinoma-2 antigen autoantibodies and zinc transporter-8 autoantibodies (ZnT8A) and measured type 1 diabetes genetic risk by genotyping 30 type 1 diabetes-associated variants at diagnosis in 1814 individuals with clinician-diagnosed type 1 diabetes (1112 adult-onset, 702 childhood-onset). We compared the overall type 1 diabetes genetic risk score (T1DGRS) and non-HLA and HLA (DR3-DQ2, DR4-DQ8 and DR15-DQ6) components with autoantibody status in those with adult-onset and childhood-onset diabetes. We also measured the T1DGRS in 1924 individuals with type 2 diabetes from the Wellcome Trust Case Control Consortium to represent non-autoimmune diabetes control participants. Results: The T1DGRS was similar in autoantibody-negative and autoantibody-positive clinician-diagnosed childhood-onset type 1 diabetes (mean [SD] 0.274 [0.034] vs 0.277 [0.026], p=0.4). In contrast, the T1DGRS in autoantibody-negative adult-onset type 1 diabetes was lower than that in autoantibody-positive adult-onset type 1 diabetes (mean [SD] 0.243 [0.036] vs 0.271 [0.026], ppppp<0.0001) than autoantibody-positive adults. In contrast to children, autoantibody-negative adults were more likely to be male (75% vs 59%), had a higher BMI (27 vs 24 kg/m2) and were less likely to have other autoimmune conditions (2% vs 10%) than autoantibody-positive adults (all pp>0.3). These findings, along with the identification of seven misclassified adults with monogenic diabetes among autoantibody-negative adults and the results of a sensitivity analysis with and without measurement of ZnT8A, suggest that the intermediate type 1 diabetes genetic risk in autoantibody-negative adults is more likely to be explained by the inclusion of misclassified non-autoimmune diabetes (estimated to represent 67% of all antibody-negative adults, 95% CI 61%, 73%) than by the presence of unmeasured autoantibodies or by a discrete form of diabetes. When these estimated individuals with non-autoimmune diabetes were adjusted for, the prevalence of autoantibody positivity in adult-onset type 1 diabetes was similar to that in children (93% vs 91%, p=0.4). Conclusions/interpretation: The inclusion of non-autoimmune diabetes is the most likely explanation for the observed lower rate of autoantibody positivity in clinician-diagnosed adult-onset type 1 diabetes. Our data support the utility of islet autoantibody measurement in clinician-suspected adult-onset type 1 diabetes in routine clinical practice. Graphical
- 10 November 2022
- Published by Springer Nature in Diabetologia
- Vol. 66 (2) , 310-320
Open AccessThe relationship between islet autoantibody status and the genetic risk of type 1 diabetes in adult-onset type 1 diabetes
Aims/hypothesis: The reason for the observed lower rate of islet autoantibody positivity in clinician-diagnosed adult-onset vs childhood-onset type 1 diabetes is not known. We aimed to explore this by assessing the genetic risk of type 1 diabetes in autoantibody-negative and -positive children and adults. Methods: We analysed GAD autoantibodies, insulinoma-2 antigen autoantibodies and zinc transporter-8 autoantibodies (ZnT8A) and measured type 1 diabetes genetic risk by genotyping 30 type 1 diabetes-associated variants at diagnosis in 1814 individuals with clinician-diagnosed type 1 diabetes (1112 adult-onset, 702 childhood-onset). We compared the overall type 1 diabetes genetic risk score (T1DGRS) and non-HLA and HLA (DR3-DQ2, DR4-DQ8 and DR15-DQ6) components with autoantibody status in those with adult-onset and childhood-onset diabetes. We also measured the T1DGRS in 1924 individuals with type 2 diabetes from the Wellcome Trust Case Control Consortium to represent non-autoimmune diabetes control participants. Results: The T1DGRS was similar in autoantibody-negative and autoantibody-positive clinician-diagnosed childhood-onset type 1 diabetes (mean [SD] 0.274 [0.034] vs 0.277 [0.026], p=0.4). In contrast, the T1DGRS in autoantibody-negative adult-onset type 1 diabetes was lower than that in autoantibody-positive adult-onset type 1 diabetes (mean [SD] 0.243 [0.036] vs 0.271 [0.026], ppppp<0.0001) than autoantibody-positive adults. In contrast to children, autoantibody-negative adults were more likely to be male (75% vs 59%), had a higher BMI (27 vs 24 kg/m2) and were less likely to have other autoimmune conditions (2% vs 10%) than autoantibody-positive adults (all pp>0.3). These findings, along with the identification of seven misclassified adults with monogenic diabetes among autoantibody-negative adults and the results of a sensitivity analysis with and without measurement of ZnT8A, suggest that the intermediate type 1 diabetes genetic risk in autoantibody-negative adults is more likely to be explained by the inclusion of misclassified non-autoimmune diabetes (estimated to represent 67% of all antibody-negative adults, 95% CI 61%, 73%) than by the presence of unmeasured autoantibodies or by a discrete form of diabetes. When these estimated individuals with non-autoimmune diabetes were adjusted for, the prevalence of autoantibody positivity in adult-onset type 1 diabetes was similar to that in children (93% vs 91%, p=0.4). Conclusions/interpretation: The inclusion of non-autoimmune diabetes is the most likely explanation for the observed lower rate of autoantibody positivity in clinician-diagnosed adult-onset type 1 diabetes. Our data support the utility of islet autoantibody measurement in clinician-suspected adult-onset type 1 diabetes in routine clinical practice. Graphical
- Open Access
- 20 June 2022
- Published by Elsevier in SSRN Electronic Journal
Exocrine Proteins Including Trypsin(ogen) as a Key Biomarker in Type 1 Diabetes
Background: Proteomic profiling can identify useful biomarkers and monozygotic (MZ) twins, discordant for a condition represent the ideal test population. We aimed to investigate and validate proteomic profiling in twins with type 1 diabetes (T1D) and in other well characterised cohorts. Methods: A broad, multiplex analysis of 4068 proteins in sera from MZ twin pairs concordant (n=43) and discordant for T1D (n=27) identified major differences which were subsequently validated by a trypsin(ogen) assay in MZ pairs concordant (n=39) and discordant (n=42) for T1D,individuals at-risk (n=195) and with T1D (n=990), as well as with non-insulin requiring adult-onset diabetes diagnosed with either autoimmune (ADA)(n=96) or type 2 diabetes (T2D) (n=291). Findings: Proteomic analysis identified major differences between exocrine enzyme levels in discordant MZ twin pairs despite strong correlation between twins, whether concordant or discordant for T1D (P<0∙01 for both). In validation experiments, trypsin(ogen) levels were lower in T1D twins compared with non-diabetic co-twins (p<0∙0001) and healthy controls (p=0∙0002). In recently-diagnosed cases, trypsin(ogen) levels were lower than in controls across a broad age range. In at-risk relatives, levels <15 ng/ml were associated with increased risk of progression (uncorr. p=0∙009). Multiple linear regression in recently-diagnosed cases showed that trypsin(ogen) levels are associated with insulin dose and diabetic ketoacidosis while age and BMI are major confounders. Interpretation: T1D is associated with altered exocrine function, even before clinical onset. Twin data suggest roles for genetic and non-genetically determined factors. Exocrine/endocrine interactions are important under-investigated factors in T1D. Funding: Diabetes UK, JDRF, British Diabetic Twin Trust, Barts Charity and EU(FP7). Declaration of Interest: The authors declare no conflict of interest. Ethical Approval: The BOX study is approved by the South Central–Oxford C National Research Ethics Committee (REC) (Ref: 15/SC/0310) while the ADDRESS-2 study has ethical approval from South Central-Berkshire REC (Ref: 10/H0505/85). Analysis of samples from the ENDIT cohort have been approved by Wales REC 6 (Ref: 19/WA/0295). The twins study was approved by Northern and Yorkshire REC (Ref: 06/MRE03/22). Adult-onset diabetes samples were approved by the UK National Research Ethics Committee (Ref:P/02/240). All participants provided informed consent either personally or by parental consent, as appropriate as mandated by the Declaration of Helsinki.
- 20 June 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessExocrine Proteins Including Trypsin(ogen) as a Key Biomarker in Type 1 Diabetes
Background: Proteomic profiling can identify useful biomarkers and monozygotic (MZ) twins, discordant for a condition represent the ideal test population. We aimed to investigate and validate proteomic profiling in twins with type 1 diabetes (T1D) and in other well characterised cohorts. Methods: A broad, multiplex analysis of 4068 proteins in sera from MZ twin pairs concordant (n=43) and discordant for T1D (n=27) identified major differences which were subsequently validated by a trypsin(ogen) assay in MZ pairs concordant (n=39) and discordant (n=42) for T1D,individuals at-risk (n=195) and with T1D (n=990), as well as with non-insulin requiring adult-onset diabetes diagnosed with either autoimmune (ADA)(n=96) or type 2 diabetes (T2D) (n=291). Findings: Proteomic analysis identified major differences between exocrine enzyme levels in discordant MZ twin pairs despite strong correlation between twins, whether concordant or discordant for T1D (P<0∙01 for both). In validation experiments, trypsin(ogen) levels were lower in T1D twins compared with non-diabetic co-twins (p<0∙0001) and healthy controls (p=0∙0002). In recently-diagnosed cases, trypsin(ogen) levels were lower than in controls across a broad age range. In at-risk relatives, levels <15 ng/ml were associated with increased risk of progression (uncorr. p=0∙009). Multiple linear regression in recently-diagnosed cases showed that trypsin(ogen) levels are associated with insulin dose and diabetic ketoacidosis while age and BMI are major confounders. Interpretation: T1D is associated with altered exocrine function, even before clinical onset. Twin data suggest roles for genetic and non-genetically determined factors. Exocrine/endocrine interactions are important under-investigated factors in T1D. Funding: Diabetes UK, JDRF, British Diabetic Twin Trust, Barts Charity and EU(FP7). Declaration of Interest: The authors declare no conflict of interest. Ethical Approval: The BOX study is approved by the South Central–Oxford C National Research Ethics Committee (REC) (Ref: 15/SC/0310) while the ADDRESS-2 study has ethical approval from South Central-Berkshire REC (Ref: 10/H0505/85). Analysis of samples from the ENDIT cohort have been approved by Wales REC 6 (Ref: 19/WA/0295). The twins study was approved by Northern and Yorkshire REC (Ref: 06/MRE03/22). Adult-onset diabetes samples were approved by the UK National Research Ethics Committee (Ref:P/02/240). All participants provided informed consent either personally or by parental consent, as appropriate as mandated by the Declaration of Helsinki.
- 22 March 2022
- Published by Springer Nature
- p. 73-91
Pathophysiology
- 26 October 2021
- Published by Springer Nature in Diabetologia
- Vol. 65 (1) , 258
Correction to: DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life
- 26 October 2021
- Published by Springer Nature in Diabetologia
- Vol. 65 (1) , 258
Correction to: DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life
- Open Access
- 16 July 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (10) , 2258-2265
DR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life
Aims/hypothesis: Among white European children developing type 1 diabetes, the otherwise common HLA haplotype DR15-DQ6 is rare, and highly protective. Adult-onset type 1 diabetes is now known to represent more overall cases than childhood onset, but it is not known whether DR15-DQ6 is protective in older-adult-onset type 1 diabetes. We sought to quantify DR15-DQ6 protection against type 1 diabetes as age of onset increased.Methods: In two independent cohorts we assessed the proportion of type 1 diabetes cases presenting through the first 50 years of life with DR15-DQ6, compared with population controls. In the After Diabetes Diagnosis Research Support System-2 (ADDRESS-2) cohort (n = 1458) clinician-diagnosed type 1 diabetes was confirmed by positivity for one or more islet-specific autoantibodies. In UK Biobank (n = 2502), we estimated type 1 diabetes incidence rates relative to baseline HLA risk for each HLA group using Poisson regression. Analyses were restricted to white Europeans and were performed in three groups according to age at type 1 diabetes onset: 0–18 years, 19–30 years and 31–50 years.Results: DR15-DQ6 was protective against type 1 diabetes through to age 50 years (OR < 1 for each age group, allp < 0.001). The following ORs for type 1 diabetes, relative to a neutral HLA genotype, were observed in ADDRESS-2: age 5–18 years OR 0.16 (95% CI 0.08, 0.31); age 19–30 years OR 0.10 (0.04, 0.23); and age 31–50 years OR 0.37 (0.21, 0.68). DR15-DQ6 also remained highly protective at all ages in UK Biobank. Without DR15-DQ6, the presence of major type 1 diabetes high-risk haplotype (either DR3-DQ2 or DR4-DQ8) was associated with increased risk of type 1 diabetes.Conclusions/interpretation: HLA DR15-DQ6 confers dominant protection from type 1 diabetes across the first five decades of life.Graphical
- 16 July 2021
- Published by Springer Nature in Diabetologia
- Vol. 64 (10) , 2258-2265
Open AccessDR15-DQ6 remains dominantly protective against type 1 diabetes throughout the first five decades of life
Aims/hypothesis: Among white European children developing type 1 diabetes, the otherwise common HLA haplotype DR15-DQ6 is rare, and highly protective. Adult-onset type 1 diabetes is now known to represent more overall cases than childhood onset, but it is not known whether DR15-DQ6 is protective in older-adult-onset type 1 diabetes. We sought to quantify DR15-DQ6 protection against type 1 diabetes as age of onset increased.Methods: In two independent cohorts we assessed the proportion of type 1 diabetes cases presenting through the first 50 years of life with DR15-DQ6, compared with population controls. In the After Diabetes Diagnosis Research Support System-2 (ADDRESS-2) cohort (n = 1458) clinician-diagnosed type 1 diabetes was confirmed by positivity for one or more islet-specific autoantibodies. In UK Biobank (n = 2502), we estimated type 1 diabetes incidence rates relative to baseline HLA risk for each HLA group using Poisson regression. Analyses were restricted to white Europeans and were performed in three groups according to age at type 1 diabetes onset: 0–18 years, 19–30 years and 31–50 years.Results: DR15-DQ6 was protective against type 1 diabetes through to age 50 years (OR < 1 for each age group, allp < 0.001). The following ORs for type 1 diabetes, relative to a neutral HLA genotype, were observed in ADDRESS-2: age 5–18 years OR 0.16 (95% CI 0.08, 0.31); age 19–30 years OR 0.10 (0.04, 0.23); and age 31–50 years OR 0.37 (0.21, 0.68). DR15-DQ6 also remained highly protective at all ages in UK Biobank. Without DR15-DQ6, the presence of major type 1 diabetes high-risk haplotype (either DR3-DQ2 or DR4-DQ8) was associated with increased risk of type 1 diabetes.Conclusions/interpretation: HLA DR15-DQ6 confers dominant protection from type 1 diabetes across the first five decades of life.Graphical
- Open Access
The absence of islet autoantibodies in clinically diagnosed older-adult onset type 1 diabetes suggests an alternative pathology, advocating for routine testing in this age group
Objective Islet autoantibodies at diagnosis are not well studied in older-adult onset (>30years) type 1 diabetes due to difficulties of accurate diagnosis. We used a type 1 diabetes genetic risk score (T1DGRS) to identify type 1 diabetes aiming to evaluate the prevalence and pattern of autoantibodies in older-adult onset type 1 diabetes. Methods We used a 30 variant T1DGRS in 1866 white-European individuals to genetically confirm a clinical diagnosis of new onset type 1 diabetes. We then assessed the prevalence and pattern of GADA, IA2A and ZnT8A within genetically consistent type 1 diabetes across three age groups (30years (n=588)). Findings In autoantibody positive cases T1DGRS was consistent with 100% type 1 diabetes in each age group. Conversely in autoantibody negative cases, T1DGRS was consistent with 93%(56/60) of 30years having type 1 diabetes. Restricting analysis to genetically consistent type 1 diabetes showed similar proportions of positive autoantibodies across age groups (92% 30years)[p=0.87]. GADA was the most common autoantibody in older-adult onset type 1 diabetes, identifying 95% of autoantibody positive cases versus 72% in those Interpretation Older adult-onset type 1 diabetes has identical rates but different patterns of positive autoantibodies to childhood onset. In clinically suspected type 1 diabetes in older-adults, absence of autoantibodies strongly suggests non-autoimmune diabetes. Our findings suggest the need to change guidelines from measuring islet autoantibodies where there is diagnostic uncertainty to measuring at least GADA in all suspected adult type 1 diabetes cases.
Open AccessThe absence of islet autoantibodies in clinically diagnosed older-adult onset type 1 diabetes suggests an alternative pathology, advocating for routine testing in this age group
Objective Islet autoantibodies at diagnosis are not well studied in older-adult onset (>30years) type 1 diabetes due to difficulties of accurate diagnosis. We used a type 1 diabetes genetic risk score (T1DGRS) to identify type 1 diabetes aiming to evaluate the prevalence and pattern of autoantibodies in older-adult onset type 1 diabetes. Methods We used a 30 variant T1DGRS in 1866 white-European individuals to genetically confirm a clinical diagnosis of new onset type 1 diabetes. We then assessed the prevalence and pattern of GADA, IA2A and ZnT8A within genetically consistent type 1 diabetes across three age groups (30years (n=588)). Findings In autoantibody positive cases T1DGRS was consistent with 100% type 1 diabetes in each age group. Conversely in autoantibody negative cases, T1DGRS was consistent with 93%(56/60) of 30years having type 1 diabetes. Restricting analysis to genetically consistent type 1 diabetes showed similar proportions of positive autoantibodies across age groups (92% 30years)[p=0.87]. GADA was the most common autoantibody in older-adult onset type 1 diabetes, identifying 95% of autoantibody positive cases versus 72% in those Interpretation Older adult-onset type 1 diabetes has identical rates but different patterns of positive autoantibodies to childhood onset. In clinically suspected type 1 diabetes in older-adults, absence of autoantibodies strongly suggests non-autoimmune diabetes. Our findings suggest the need to change guidelines from measuring islet autoantibodies where there is diagnostic uncertainty to measuring at least GADA in all suspected adult type 1 diabetes cases.
- 22 December 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (43) , 5564-5572
Long-Term Metabolic Consequences in Patients with a History of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic complication of pregnancy. Universal guidelines on gestational diabetes have been impeded by the long-term controversies on its definition and screening strategies. The prevalence of gestational diabetes is rising all over the world, is significantly influenced by ethnicity and its rise is mainly attributed to increasing maternal obesity and age. Gestational diabetes mellitus has important long-term implications, including gestational diabetes recurrence, increased risk for developing type 2 diabetes, metabolic syndrome and cardiovascular disease for the mother. Gestational diabetes mellitus may be viewed as a chronic metabolic disorder that is identified in women during gestation and may provide a unique opportunity for the early identification and primary prevention of type 2 diabetes mellitus and cardiovascular disease in these women. In this mini-review, the evolution of screening tests for gestational diabetes and guidelines are briefly described and metabolic and cardiovascular long-term consequences of women with a history of gestational diabetes are summarized. A summary of our own St. Mary’s Hospital-UK Research series on long-term metabolic consequences of 368 women with a history of gestational diabetes of 3 different ethnic groups and 482 control women is also included. We found that approximately 2 years following delivery, 37% of women with a history of gestational diabetes had abnormal glucose concentrations, but, most importantly, even those who were normoglycaemic, postpartum displayed metabolic abnormalities on detailed testing. Future research needs to focus on the prevention of gestational diabetes long-term complications, but also in identification of pre-pregnancy predictors and risk reduction before conception.
- 22 December 2020
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 26 (43) , 5564-5572
Long-Term Metabolic Consequences in Patients with a History of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic complication of pregnancy. Universal guidelines on gestational diabetes have been impeded by the long-term controversies on its definition and screening strategies. The prevalence of gestational diabetes is rising all over the world, is significantly influenced by ethnicity and its rise is mainly attributed to increasing maternal obesity and age. Gestational diabetes mellitus has important long-term implications, including gestational diabetes recurrence, increased risk for developing type 2 diabetes, metabolic syndrome and cardiovascular disease for the mother. Gestational diabetes mellitus may be viewed as a chronic metabolic disorder that is identified in women during gestation and may provide a unique opportunity for the early identification and primary prevention of type 2 diabetes mellitus and cardiovascular disease in these women. In this mini-review, the evolution of screening tests for gestational diabetes and guidelines are briefly described and metabolic and cardiovascular long-term consequences of women with a history of gestational diabetes are summarized. A summary of our own St. Mary’s Hospital-UK Research series on long-term metabolic consequences of 368 women with a history of gestational diabetes of 3 different ethnic groups and 482 control women is also included. We found that approximately 2 years following delivery, 37% of women with a history of gestational diabetes had abnormal glucose concentrations, but, most importantly, even those who were normoglycaemic, postpartum displayed metabolic abnormalities on detailed testing. Future research needs to focus on the prevention of gestational diabetes long-term complications, but also in identification of pre-pregnancy predictors and risk reduction before conception.
- Open Access
- 9 January 2020
- Published by Springer Nature in Diabetologia
- Vol. 63 (3) , 486-496
A pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomised controlled trial
Aims/hypothesis: This randomised controlled trial was performed in India and the UK in people with prediabetes to study whether mobile phone short message service (SMS) text messages can be used to motivate and educate people to follow lifestyle modifications, to prevent type 2 diabetes.Methods: The study was performed in people with prediabetes (n = 2062; control:n = 1031; intervention:n = 1031) defined by HbA1c≥42 and ≤47 mmol/mol (≥6.0% and ≤6.4%). Participants were recruited from public and private sector organisations in India (men and women aged 35–55 years) and by the National Health Service (NHS) Health Checks programme in the UK (aged 40–74 years without pre-existing diabetes, cardiovascular disease or kidney disease). Allocation to the study groups was performed using a computer-generated sequence (1:1) in India and by stratified randomisation in permuted blocks in the UK. Investigators in both countries remained blinded throughout the study period. All participants received advice on a healthy lifestyle at baseline. The intervention group in addition received supportive text messages using mobile phone SMS messages 2–3 times per week. Participants were assessed at baseline and at 6, 12 and 24 months. The primary outcome was conversion to type 2 diabetes and secondary outcomes included anthropometry, biochemistry, dietary and physical activity changes, blood pressure and quality of life.Results: At the 2 year follow-up (n = 2062; control:n = 1031; intervention:n = 1031), in the intention-to-treat population the HR for development of type 2 diabetes calculated using a discrete-time proportional hazards model was 0.89 (95% CI 0.74, 1.07;p = 0.22). There were no significant differences in the secondary outcomes.Conclusions/interpretation: This trial in two countries with varied ethnic and cultural backgrounds showed no significant reduction in the progression to diabetes in 2 years by lifestyle modification using SMS messaging.Trial registration: The primary study was registered onwww.ClinicalTrials.gov(India, NCT01570946; UK, NCT01795833).Funding: The study was funded jointly by the Indian Council for Medical Research and the UK Medical Research Council.
- 9 January 2020
- Published by Springer Nature in Diabetologia
- Vol. 63 (3) , 486-496
Open AccessA pragmatic and scalable strategy using mobile technology to promote sustained lifestyle changes to prevent type 2 diabetes in India and the UK: a randomised controlled trial
Aims/hypothesis: This randomised controlled trial was performed in India and the UK in people with prediabetes to study whether mobile phone short message service (SMS) text messages can be used to motivate and educate people to follow lifestyle modifications, to prevent type 2 diabetes.Methods: The study was performed in people with prediabetes (n = 2062; control:n = 1031; intervention:n = 1031) defined by HbA1c≥42 and ≤47 mmol/mol (≥6.0% and ≤6.4%). Participants were recruited from public and private sector organisations in India (men and women aged 35–55 years) and by the National Health Service (NHS) Health Checks programme in the UK (aged 40–74 years without pre-existing diabetes, cardiovascular disease or kidney disease). Allocation to the study groups was performed using a computer-generated sequence (1:1) in India and by stratified randomisation in permuted blocks in the UK. Investigators in both countries remained blinded throughout the study period. All participants received advice on a healthy lifestyle at baseline. The intervention group in addition received supportive text messages using mobile phone SMS messages 2–3 times per week. Participants were assessed at baseline and at 6, 12 and 24 months. The primary outcome was conversion to type 2 diabetes and secondary outcomes included anthropometry, biochemistry, dietary and physical activity changes, blood pressure and quality of life.Results: At the 2 year follow-up (n = 2062; control:n = 1031; intervention:n = 1031), in the intention-to-treat population the HR for development of type 2 diabetes calculated using a discrete-time proportional hazards model was 0.89 (95% CI 0.74, 1.07;p = 0.22). There were no significant differences in the secondary outcomes.Conclusions/interpretation: This trial in two countries with varied ethnic and cultural backgrounds showed no significant reduction in the progression to diabetes in 2 years by lifestyle modification using SMS messaging.Trial registration: The primary study was registered onwww.ClinicalTrials.gov(India, NCT01570946; UK, NCT01795833).Funding: The study was funded jointly by the Indian Council for Medical Research and the UK Medical Research Council.